Gilead Sciences, Inc.

Sell-side

Financial Advisor, July 2020

Gilead Sciences, Inc.
Sale of Spleen Tyrosine Kinase (SYK) Inhibitor Portfolio to Kronos Bio

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.

More Like This

Jul 2023

Sold Majority Stake in hg medical to Astorg Mid-Cap

Exclusive Financial Advisor

View Details >
May 2023
Jounce Therapeutics Logo

Acquired by Concentra Biosciences

Exclusive Financial Advisor

View Details >
Mar 2023

Smile Source, a Portfolio Company of Brazos Private Equity Partners, has Partnered with Incline Equity Partners

Exclusive Financial Advisor

View Details >